25 авг. 2016 г. · Ovarian cancer is a global problem, is typically diagnosed at a late stage and has no effective screening strategy.

Matulonis has led several PARP inhibitor, anti-angiogenic agent, immunotherapy, and combination trials for ovarian cancer in the United States and ...

Ursula A. Matulonis, MD, is Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical ...

Surgery and combination treatment with carboplatin and paclitaxel are the standard of care for patients with newly diagnosed disease, although the use of ...

25 авг. 2016 г. · & Matulonis, U. A. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin.

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses three important studies focusing on newer therapies for patients with recurrent ...

Dr. Matulonis' research focuses on new treatments for gynecologic malignancies, with a particular emphasis on ovarian cancer. She is the principal investigator ...

20 июн. 2022 г. · Ursula A. Matulonis, MD, discusses the current treatment landscape of recurrent ovarian cancer.

15 сент. 2023 г. · Topic: Drug Development for Ovarian Cancer: Challenges and Successes Ursula Matulonis, MD is Chief and Director of the Division of ...

Ursula A. Matulonis, MD, of Dana-Farber Cancer Center discusses the ENGOT-OV16/NOVA study, which initially showed that niraparib maintenance therapy ...